Justifying R&D Research
I recently read that the U.S. is spending more now on tort litigation than it is on research and development. Unfortunately, there’s not much of an export market in torts, so I hope we will find a way to get our priorities right before China and India (and near everyone else) eats our lunch.
On my site AeroGo today I used one example, the recent discovery that weightlessness affects the immune system in a way somewhat similar to HIV, as a springboard for discussing why it’s often hard to justify exploration and research beforehand, even though we have hundreds of years of human experience that clearly show a big long-term payoff.
The problem is that we usually get it wrong when we try to predict what we’ll find and the timetable for reaping benefits. We find something unexpected and seemingly disappointing, that in the long run ends up being way bigger than what we were looking for. Columbus was looking for spices and gold. There actually was gold, just not in the West Indies. Columbus apparently had failed, because the Spanish didn’t realize at first that they’d discovered two whole continents.
The U.S. needs to aim higher and stop quibbling so much about R&D. While funding needs to increase in the private sector (in case you haven’t noticed the federal government is already in hock up to its eyeballs), even more important than an increase is the need to get a lot better at the poorly-understood techniques of targeting and scaling of R&D investment.
We need to spend less per project early on, spread funds around more broadly, and most of all invest much more consistently and for the long term, something difficult to do in the U.S., at least in government agencies and publicly-traded companies.
